25 Years Young: An Interview with Bruce Carter, President and CEO of ZymoGenetics.

Fintan Walton, CEO of PharmaVentures, talks exclusively to Bruce Carter, President and CEO of ZymoGenetics, a company that celebrated its 25th anniversary on 22 June 2006. Bruce discusses a number of aspects of ZymoGenetics' operations, including its relationship with previous owners Novo Nordisk, its alliance with Serono and its drug development model. Bruce also shares his views and advice on biotech acquisitions and the key characteristics of a successful biotech CEO.

About Bruce Carter

Dr Bruce Carter joined ZymoGenetics in 1986 as Vice President of Research and Development. After a period as Corporate Executive Vice President and Chief Scientific Officer with Novo Nordisk A/S, Bruce became CEO of ZymoGenetics in April 1998. Earlier in his career, he worked at G.D. Searle & Co and was a Lecturer at Trinity College, University of Dublin.

About ZymoGenetics

ZymoGenetics is a protein-focused biotechnology company based in Seattle, WA, US. Three university professors founded the company in 1981 and, in 1988, it was acquired by Novo Nordisk, becoming a wholly owned subsidiary for 12 years. During this period ZymoGenetics contributed to the development of several of Novo Nordisk's current products.

In November 2000, ZymoGenetics was re-established as an independent biotechnology company, raising US$150 million in a private placement financing. Subsequently, ZymoGenetics completed an initial public offering and, on 1 February 2002, began trading on the Nasdaq stock exchange.